Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

25
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

488
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
488
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

19
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

688
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
688
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

27
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
27

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leaving No Metal Behind in PCI: Is This Concept Ready for Primetime?

Circulation. Cardiovascular interventions·2026
Same author

Revascularization for Ischemic Cardiomyopathy: Disproving the 45-Year-Old Concept of Hibernating Myocardium.

Annual review of medicine·2026
Same author

Early outcomes of off-label transcatheter tricuspid valve repair/replacement in the STS/ACC TVT registry.

American heart journal·2026
Same author

Semaglutide in Peripheral Artery Disease: A Step Toward Sex-Specific Care.

Journal of the American College of Cardiology·2025
Same author

Optimizing Pre-to-Post Discharge Transition of Care in Patients Hospitalized for Heart Failure - Part 3 of the International Expert Opinion Series on Acute Heart Failure Management.

Journal of cardiac failure·2025
Same author

Addressing Diastolic Dysfunction in the Congenital Heart Population.

Current cardiology reports·2025

Related Experiment Video

Updated: Aug 26, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K

Device Therapy for Heart Failure with Preserved Ejection Fraction.

Husam M Salah1, Allison P Levin2, Marat Fudim3

  • 1Department of Medicine, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA.

Cardiology Clinics
|October 9, 2022
PubMed
Summary

Device therapies offer new hope for heart failure with preserved ejection fraction (HFpEF), a complex condition lacking effective drugs. This review explores innovative device treatments targeting HFpEF

Keywords:
Atrial shuntBaroreflex activation therapyCardiac contractility modulationDevice therapyHFpEFInteratrial shuntPhrenic nerve stimulationSplanchnic nerve modulation

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.4K

Related Experiment Videos

Last Updated: Aug 26, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.4K

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Research

Background:

  • Heart failure with preserved ejection fraction (HFpEF) presents a significant clinical challenge due to its heterogeneity.
  • Limited effective pharmacologic therapies exist for HFpEF, necessitating alternative treatment strategies.

Purpose of the Study:

  • To review current and emerging device-based therapeutic approaches for HFpEF.
  • To focus on structural, autonomic, and respiratory modulation interventions.

Main Methods:

  • Systematic review of device-based therapies for HFpEF.
  • Categorization of interventions into structural, autonomic, and respiratory modulation.

Main Results:

  • Exploration of left-to-right atrial shunts for structural modulation.
  • Discussion of cardiac contractility modulation devices.
  • Overview of autonomic modulation techniques like baroreflex activation and splanchnic nerve stimulation.
  • Examination of respiratory modulation via phrenic nerve stimulation.

Conclusions:

  • Device therapy represents a promising frontier for managing HFpEF.
  • These interventions aim to address common pathophysiologic features across diverse HFpEF etiologies.